Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase 2/3 Terminated 8 enrolled Xiaojun Chen

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To investigate the efficacy of weight management plus megestrol acetate in obese patients with early endometrioid carcinoma（EEC）asking for fertility-sparing treatment

Timeline

Start: 2022-05-01
Primary completion: 2026-02-28
Completion: 2026-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Megestrol Acetate	Other / unclassified	160 mg	Oral

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Summary

Timeline

Drugs

Indications